Structure Therapeutics Inc. (GPCR) Price Target Analysis
Wall Street analyst price targets, ratings consensus & upside potential · Updated May 1, 2026
Current Price
$39.15
Price Target
$114.75
Target Range
$90.00 — $145.00
Analyst Rating
Buy
Forward P/E—
Trailing P/E-16.3x
Forward PEG—
Implied Growth+37.2%
Median Target$113.50
Analyst Spread47.9%
Price Forecast (1 Year)
Last 12 months price action with 12-month analyst target path
Bear Case
$90
+129.9%
Consensus
$115
+193.1%
Bull Case
$145
+270.4%
GPCR Price Target Analysis
Updated May 7, 2026As of May 7, 2026, Structure Therapeutics Inc. (GPCR) has a Wall Street consensus price target of $114.75, based on estimates from 14 covering analysts. With the stock currently trading at $39.15, this represents a potential upside of +193.1%. The company has a market capitalization of $2.25B.
Analyst price targets range from a low of $90.00 to a high of $145.00, representing a 48% spread in expectations. The median target of $113.50 aligns closely with the consensus average.
The current analyst consensus rating is Buy, with 14 analysts rating the stock as a Buy or Strong Buy,0 rating it Hold, and 0 rating it Sell or Strong Sell. This overwhelmingly bullish sentiment suggests analysts see significant catalysts for upside ahead.
From a valuation perspective, GPCR trades at a trailing P/E of -16.3x. Analysts expect EPS to grow +37.2% over the next year.
Investment Context: Price targets represent analyst expectations for the next 12 months and should be considered alongside your own research. Targets are based on analysts' assumptions about earnings growth, margins, and market conditions which may change. For sector-specific context, view other Healthcare stocks.
Analyst Sentiment Comparison
Industry Peer AnalysisAvg Peer Upside+95.1%
Avg Forward P/E15.2x
Peers with Coverage10 / 10
| Company | Market Cap | Price | Target | Upside | Rating | Fwd P/E | Analysts |
|---|---|---|---|---|---|---|---|
 CHRSCoherus Oncology, Inc. | $213M | $1.76 | $6.02 | +242.0% | Buy | — | 16 |
 RVMDRevolution Medicines, Inc. | $30.3B | $142.51 | $154.80 | +8.6% | Buy | — | 22 |
 KYMRKymera Therapeutics, Inc. | $6.9B | $84.63 | $117.06 | +38.3% | Buy | — | 26 |
 ARWRArrowhead Pharmaceuticals, Inc. | $10.9B | $77.95 | $81.22 | +4.2% | Buy | — | 20 |
 CGEMCullinan Therapeutics, Inc. | $905M | $14.72 | $31.14 | +111.5% | Buy | — | 8 |
 VKTXViking Therapeutics, Inc. | $3.7B | $31.58 | $100.75 | +219.0% | Buy | — | 24 |
 PEPGPepGen Inc. | $123M | $1.79 | $7.00 | +291.1% | Buy | — | 6 |
 NVONovo Nordisk A/S | $203.5B | $45.79 | $47.00 | +2.6% | Buy | 2.1x | 39 |
 LLYEli Lilly and Company | $921.2B | $974.96 | $1258.47 | +29.1% | Buy | 28.2x | 45 |
 TERNTerns Pharmaceuticals, Inc. | $4.6B | $52.95 | $55.56 | +4.9% | Buy | — | 16 |
Upside Potential Comparison
PEPGCHRSVKTXCGEMKYMRLLYRVMDTERNSee GPCR's True Return
Price is only half the story. See total return with reinvested dividends.
Launch CalculatorIs GPCR Undervalued?
DCF intrinsic value, peer multiples, and analyst estimates — see what the stock is really worth.
View ValuationCompare GPCR vs DBVT
Side-by-side business, growth, and profitability comparison vs DBV Technologies S.A..
Start ComparisonGPCR — Frequently Asked Questions
Quick answers to the most common questions about buying GPCR stock.
What is the GPCR stock price target for 2026?
The consensus Wall Street price target for GPCR is $114.75, representing 193.1% upside from the current price of $39.15. With 14 analysts covering the stock, this strong upside suggests significant value not yet reflected in today's share price.
Is GPCR a buy, sell, or hold?
GPCR has a consensus rating of "Buy" based on 14 Wall Street analysts. The rating breakdown is predominantly bullish, with 14 Buy/Strong Buy ratings. The consensus 12-month price target of $114.75 implies 193.1% upside from current levels.
Is GPCR stock overvalued or undervalued?
GPCR's current price is $39.15 with a consensus target of $114.75 (193.1% implied move). Analyst estimates suggest the stock is undervalued at current levels.
How high can GPCR stock go?
The most bullish Wall Street analyst has a price target of $145 for GPCR, while the most conservative target is $90. The consensus of $114.75 represents the median expectation. These targets typically reflect 12-month expectations.
How many analysts cover GPCR stock?
GPCR is moderately covered, with 14 analysts providing price targets and ratings. Of these, 0 have Strong Buy ratings, 14 have Buy ratings, 0 recommend Hold, and 0 have Sell or Strong Sell ratings. Higher analyst coverage generally indicates greater institutional interest and more reliable consensus estimates.
What is the GPCR stock forecast?
The 12-month GPCR stock forecast based on 14 Wall Street analysts shows a consensus price target of $114.75, with estimates ranging from $90 (bear case) to $145 (bull case). The median consensus rating is "Buy".
Should I buy GPCR stock?
Wall Street analysts are very optimistic on GPCR, with a "Buy" consensus rating and $114.75 price target (193.1% upside). 14 of 14 analysts rate it Buy or Strong Buy. This information is for educational purposes only. Always conduct your own research, consider your financial situation, and consult a financial advisor before making investment decisions.
Why do GPCR price targets vary so much?
GPCR analyst price targets range from $90 to $145, a 48% moderate spread showing some variance in outlooks. Differences stem from varying assumptions about revenue growth, profit margins, competitive dynamics, and valuation multiples. The $114.75 consensus represents the middle ground.